StockUS listing USVIMGFPINKHealthcareGrowth Machine

Vimian Group AB (publ)(VIMGF) Stock Analysis | Healthcare

USD --+0.00%
Reward66High
Risk50Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.74Bn
Reward Ratingⓘ66 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ50 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on VIMGF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Vimian Group AB (publ)?

Vimian Group AB (publ) engages in the animal health business worldwide.

AI Brief Pro

The brief on Vimian Group AB (publ)

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Vimian Group AB (publ)?

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.74B, and a P/E ratio of 39.6x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (66)

Similar stocks to compare

A short list of Diagnostics & Research names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDiagnostics & Research
P/E Ratio39.5714
Beta1.419
Insider Activity
12M windowNo data
No insider activity data available for this ticker.